search icon
  • Print
  • ShareThis
  • Text Size
  • Continuing Medical Education Credit for CID/JID/OFID Manuscript Reviewers

    The Infectious Diseases Society of America offers category 1 CME credit for reviewing manuscripts. Only reviews received on time and judged satisfactory by the Editor(s) responsible for the particular manuscript will be eligible for CME credit. We only provide CME credit to reviewers if they request CME credit at the time they complete their review.

    The features that contribute most importantly to the quality of manuscript reviews for the Journal include: adherence to reviewer guidelines, specificity and accuracy, completeness, usefulness of recommendations to both editors and authors, tone, internal consistency, and mindfulness of the needs of our readers and the medical community as a whole.

    To prepare a high quality review, the reviewer should consider existing evidence when preparing his or her comments. The reviewer should place the current work in the context of existing evidence in the area, describe the unique contributions of the current work, and comment on any inconsistencies of the current work with previous research in your area.

    You will be notified via email if your review of the assigned manuscript was completed on time and if it met our criteria for CME credit.

    Accreditation Statement

    The Infectious Diseases Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.  IDSA designates each manuscript review for a maximum of 3 AMA PRA Category 1 Credit(s)TM.  Physicians should only claim credit commensurate with the extent of their participation in the activity.  Physicians are eligible for up to 3 CME credits for each manuscript review, up to a total of 15 per year.


    Through the manuscript peer review process for CID, JID, or OFID, you should be able to:

    • integrate new discoveries or observations in infectious disease research that can be applied in your work
    • use information resources that improve your ability to treat patients or to conduct research in infectious diseases
    • identify articles that provide relevant, new data about infectious diseases that could result in additional knowledge
    • apply new information that could result in improved healthcare outcomes

    Disclosure Information 

    In compliance with ACCME’s Standards for Commercial Support of Continuing Medical Education, anyone in a position to influence content is required to disclose any real or apparent conflicts of interest before participating in a CME-accredited educational activity. IDSA, in collaboration with CID, JID and OFID, identifies and resolves all conflicts of interest prior to manuscript reviews.

    CID Editors Disclosures 



    Robert T. Schooley: Advisory/Consultant: VIR; Stocks/Bonds: Antiva Biosciences; Advisory/Consultant; Stocks/Bonds: CytoDyn; Scientific Advisory Board: Monogram Biosciences, Gilead Sciences.


    Deputy Editor

    Ferric C. Fang: Advisory/Consultant/Honoraria: BioFire, Cepheid; Advisory/Consultant: ELITech; Supplies for Research Project: Luminex; Research Grant: Cepheid.


    Assistant Deputy Editor

    Barbara D. Alexander: Advisory/Consultant: Scynexis, Lediant, Cidara, Astellas; Research Grants: Shire, Gilead, Scynexis, Astellas.


    Associate Editors

    Constance A. Benson: Advisory/Consultant: GlaxoSmithKline, MBio Diagnostics; Research Grant: Gilead Sciences.

    Carlos del Rio: Advisory/Consultant: ViiV Healthcare.

    Kathryn N. Edwards: Nothing to disclose.

    Vance Fowler: Advisory/Consultant/Honoraria: Bayer, Contrafect, Janssen, xBiotech, Arsanis, Moderna, Genentech, Basilea; Polyphor; Cidara, Grant Downing; Actavis; Royalties: Up-to-Date; Advisory/Consultant: Basilea, Debiopharm; Research Grants: Karius / MedImmune, Allergan/Contrafect, Genentech/Basilea; Committee Chair: Novartis.

    David N. Fredricks: Patent/copyright/license: BD.

    Barbara E. Murray: Advisory/Consultant/Honoraria: Back Bay Life Science Adv; Decibio; Biostrategies Group, Decile.Ten Communications (Cempra Pharmaceuticals), Paratek; Research Grants: Forest/Actavis; Cubist/Merck; Theravance; Royalties: UpToDate, ASM

    Peter G. Pappas: Advisory/Consultant: Cidara, Vical, Scynexis; Mayne Pharmaceuticals; Research Grants: Astellas, IMMY, Cidara, Merck

    Robin Patel: Advisory/Consultant: Curetis, Qvella, St. Jude, Beckman Coulter; Morgan Stanley; Heraeus Medical GmbH; CORMATRIX; Specific Technologies; Diaxonit; Selux Dx; GenMarkDiagnostics; LBT Innovations; PathoQuest; Genentech; DSMB: Actelion; Royalties: UpToDate; IDBR Course; Research Grants: CD Diagnostics, BioFire, Curetis, Merck, Huchison Biofilm Medical Solutions, Accelerate Diagnostics, Allergan, Medicines Company

    David L. Paterson: Advisory/Consultant/Honoraria: Merck, Pfizer, Achaogen, GlaxoSmithKline; Advisory Role: Shionogi; Research Grant: Merck

    David A. Pegues: Advisory/Consultant: DaVita/Total Renal Care; Chair, Data Safety Monitoring Board: Seres Pharmaceutical

    William A. Petri, Jr: Advisory/Consultant: Perrigo Nutritionals; TechLab

    Stephanie N. Taylor; Advisory/Consultant: GlaxoSmithKline; Research Grants: Hologic, GlaxoSmithKline, Becton-Dickinson

    David L. Thomas: Advisory/Consultant: Merck; Royalties: Up-to-Date Associate Statistical Editor.

    Victor de Gruttola: Advisory/Consultant: Biogen, Baylor, BMS, Daiichi Sankyo, Dynavax, Genocea, Gilead, GSK, Lilly, Merck, Novo Norodisk, Prolong Pharma, Roche, ViiV


    JID Editors Conflict of Interest Disclosures



    Martin Hirsch: Nothing to disclose


    Deputy Editor

    David Hooper: Consultant: Macrolide Pharmaceuticals, Shionogi, Melinta Therapeutics, Selux  Diagnostics, Bacterioscan,  Cepheid


    Associate Editors

    Ann Arvin: Nothing to disclose

    Marcel Behr: Nothing to disclose

    Raymond Chung: Research Grants: Gilead, BMS, Janssen, Abbvie, Merck, Boehringer Ingelheim; Other: Alnylam

    Peter Densen: Personal Fees: Achillion, Ionis

    Joseph Kovacs:  Personal Fees: Healthcare Infection Society; Non-financial support: Merck; Other: Matinas, Inc; Patent related to Pneumocystis and IL-2 in HIV infection with royalties paid

    Daniel Kuritzkes: Personal Fees: Abivax, Bionor, Bristol-Myers Squibb, CytoDyn, GlaxoSmithKline, ViroStatics, InnaVirVax, Teva, Seres, Roche, Oncolys, United Bio-Pharma; Research grants and personal fees: Gilead, Merck, ViiV, Research grants: Janssen, Palisades Therapeutics

    Stuart Levitz: Nothing to disclose

    William Schaffner: Personal Fees: Merck, Pfizer, Dynavax, Seqirus, SutroVax, Shionogi

    Jane Schwebke, Research Grants and Personal Fees: Hologic, Symbiomix, Scynexis, Toltec Pharmaceuticals, StarPharma; Research grants: BD Diagnostics, Curatek, Viamet, Gage Pharmaceuticals

    Frederick Southwick: Nothing to disclose 

    Peter Weller: Nothing to disclose

    Richard Whitley: Personal Fees: Merck, Glaxo Smith Kline, George Washington University CME Department, American Academy of Pediatrics-South Carolina Chapter; Other: Gilead Sciences, Inc., Kite-A Gilead Company

    Statistical Editors

    Daniel Caffrey: Nothing to disclose

    Michael Hughes: Nothing to disclose

    Sarah Walker: Nothing to disclose


    OFID (Open Forum Infectious Diseases) Editors Conflict of Interest Disclosures 



    Paul Sax: Advisory/Consultant: AbbVie, Gilead; GSK/ViiV; Janssen; Merck


    Associate Editors

    Jonathan Blum: Nothing to disclose

    Johanna Daily: Did not disclose

    Kimberly Hanson: Nothing to disclose

    Keith Kaye: Advisory/Consultant/Honoraria: Allergan, Bayer, Melinta, Nabriva, Paratek, Shinogi

    Merck, Zavante, Xellia; Research Grant: Merck

    Jonathan Li: Advisory/Consultant: Merck, Gilead, United Biopharma

    Maunank Shah: Patent: Emocha Mobile Health; Advisory/Consultant: Gilead; Research Grant: ViiV Health Care

    Abigail Zuger: Nothing to disclose


| HIVMA | Contact Us

© Copyright IDSA 2018 Infectious Diseases Society of America

Full Site Mobile Site